Recombinant Human AXL /UFO Protein (rh AXL / UFO) Ala 26 - Pro 449 (Accession # AAH32229) was produced in human 293 cells (HEK293) at ACRObiosystems.
rh AXL / UFO, fused with polyhistidine tag at the C-terminus, has a calculated MW of 46.6 kDa. The predicted N-terminus is Ala 26. DTT-reduced Protein migrates as 60-70 kDa due to glycosylation.
Less than 1.0 EU per μg of the rh AXL / UFO by the LAL method.
>92% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Authors: Goldstein Neil et al.
Journal: United States Patent Application 20160318995
Application: Phage Library Screening
AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.